USPTO serial 79149152
SYSTEMETRIC
Reviewed by CopyMark Law Group
Reg. 4774665Status 706Registered
- Filing date
- Status date
- Registration date
- Jul 21, 2015
- Examiner
- DINALLO, KEVIN M
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with SYSTEMETRIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey A. Smith
Jeffrey A. Smith Millen White Zelano and Branigan2200 Clarendon BoulevardSuite 1400Arlington, VA 22201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use ] | SECTION 71 - CANCELLED | — |
| 009 | [ Scientific apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometry analyzers for cellular analysis; scientific apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometers for single cell and population based cellular analysis; Laboratory apparatus and instruments, namely, protein separation and isolation instruments, flow cytometers, and laboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growing, maintaining, evaluating and quality control of cell cultures, automated liquid dispensing, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes; chemistry apparatus and instruments for maintaining, evaluating and quality control of cell cultures, automated liquid dispensing of compound preparations and chemical reagents, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes ] | SECTION 71 - CANCELLED | — |
| 042 | Scientific research and development; scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing services [ and protein isolation ] for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect, and scientific research and development relating thereto; Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research, drug discovery and characterization of compound effect, [ and protein separation, isolation and characterization; ] scientific research services; scientific testing and analysis in the fields of pharmaceutical research, drug discovery and characterization of compound effect, [ and protein separation, isolation and characterization; ] computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] pharmaceutical research and development; Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, [ and protein separation, isolation and characterization; ] scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research; provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AsedaSciences AG
- Other trademarks owned by AsedaSciences AG
- Other trademarks owned by AsedaSciences AG
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named SYSTEMETRIC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| May 19, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| May 18, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 20, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 21, 2024 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Apr 4, 2024 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 7, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Mar 28, 2023 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Mar 27, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Feb 22, 2023 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Feb 22, 2023 | INPC | INVALIDATION PROCESSED | — |
| Jan 1, 2023 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 1, 2022 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| May 1, 2022 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Apr 7, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 16, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 21, 2021 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jul 21, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 4, 2016 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 2, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 2, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 21, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 21, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 5, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 5, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 2, 2015 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 15, 2015 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 15, 2015 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 15, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 27, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 27, 2015 | ALIE | ASSIGNED TO LIE | — |
| Mar 9, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 27, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 26, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 26, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 11, 2014 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 26, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 26, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 26, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 25, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2014 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Aug 22, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 21, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 2, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 29, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 19, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |